Retatrutide at ADA 2026: TRIUMPH-1 and TRANSCEND-T2D-1 Deliver — and Get Published in The Lancet

The American Diabetes Association (ADA) 2026 Scientific Sessions, held in New Orleans beginning June 5, gave the retatrutide program its biggest stage yet. On Saturday, June 6, a dedicated symposium, “Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Retatrutide,” went through the full results of two pivotal Phase 3 trials: TRIUMPH-1 in obesity and TRANSCEND-T2D-1 in type 2 diabetes. TRANSCEND-T2D-1 was also published in The Lancet the same day, turning a press-release topline into peer-reviewed evidence.

Here is what was presented, what changed from the earlier topline numbers, and why the data on other conditions may matter more than the headline weight-loss figure.

TRANSCEND-T2D-1: now peer-reviewed in The Lancet

TRANSCEND-T2D-1 enrolled 537 adults with type 2 diabetes across 48 sites in the United States, Mexico, and India, not controlled by diet and exercise alone (no background glucose-lowering drug), with a mean baseline HbA1c of 7.9%. The published 40-week results:

Between 82% and 89% of participants across the retatrutide doses reached an HbA1c below 7.0%, the standard treatment target, and 75-83% reached the tighter 6.5% threshold. Both HbA1c and weight improved with each dose step up to 12 mg. No severe hypoglycemia was reported in any arm, which matters because retatrutide’s glucagon-receptor activity can raise glucose.

One small but telling detail: the peer-reviewed numbers differ slightly from the March topline. Early estimates had suggested the HbA1c reduction might level off at the 9 mg dose. The published data instead show a clean dose-response, with 12 mg giving both the best blood sugar control and the most weight loss. It is a reminder of why peer-reviewed publication matters, and why a knowledge base should update to the published figures rather than stick with the press release.

TRIUMPH-1: the weight-loss headline held up

The obesity trial’s numbers, first reported May 21, were confirmed in the ADA presentation. In 2,339 adults with obesity or overweight plus at least one weight-related condition (no diabetes), mean weight loss at 80 weeks reached:

• 4 mg: -19.0% (-47.2 lbs)
• 9 mg: -25.9% (-64.4 lbs)
• 12 mg: -28.3% (-70.3 lbs)

Nearly half of the 12 mg group (45.3%) lost at least 30% of their body weight, and 65.3% ended the trial with a BMI below 30, meaning they were no longer clinically obese. Those figures had already made TRIUMPH-1 the strongest pivotal obesity result on record. The more interesting part of the ADA presentation, though, was what happened to the related conditions.

The multisystem story: beyond the scale

Because TRIUMPH-1 enrolled people with weight-related conditions, it included nested “basket” analyses for two common, burdensome ones. The results:

A 73.1% reduction in knee-osteoarthritis pain, inside the general obesity trial, echoes the dedicated TRIUMPH-4 trial, which reported a 75.8% WOMAC pain reduction at 9 mg. A 60.6% reduction in the apnea-hypopnea index sits squarely in the range that earned tirzepatide its obstructive-sleep-apnea indication through the SURMOUNT-OSA program.

Update, October 2026: Lilly’s June release gave the sleep apnea figure as “up to” 60.6% without naming a dose. The full results, published in NEJM on October 20, 2026, showed the largest fall in the apnea-hypopnea index at 9 mg (-34.3 events per hour, against -31.7 at 12 mg). See retatrutide and sleep apnea.

This is why it matters strategically. Eli Lilly has signaled that it plans to seek labeling for obstructive sleep apnea and knee osteoarthritis as well as obesity. TRIUMPH-1’s nested baskets supply supporting evidence for all three from a single pivotal trial, which is an efficient position to be in with regulators.

What this means for the timeline

None of the ADA data changed the regulatory calendar at the time. The change came seven weeks later: on July 23, 2026, with TRIUMPH-2 and TRIUMPH-3 reported, Eli Lilly said it planned to submit a Biologics License Application in Q1 2027 (see TRIUMPH-2 and TRIUMPH-3 results). A standard review would place a possible approval decision in the first half of 2028, or late 2027 with Priority Review. Lilly now says it plans to file no later than the first quarter of 2027, and the FDA ruled on October 2, 2026 that retatrutide is a drug, so the application must be a New Drug Application (NDA); Lilly is contesting that in court and has not said which pathway it will use (the FDA ruling).

At the time of ADA, two core readouts were still outstanding: TRIUMPH-2 (obesity with type 2 diabetes, 1,152 participants) and TRIUMPH-3 (obesity with established cardiovascular disease, 1,949 participants). Both reported topline results on July 23, 2026, and TRIUMPH-2 was published in The Lancet on September 29, 2026.

The bottom line

ADA 2026 did two things for retatrutide. It moved the diabetes data from topline into the peer-reviewed literature. And it widened the obesity story from a single number, 28.3% weight loss, into a case that also covers joints and sleep. For a drug that is still investigational and at least a year from any approval decision, that is about as strong a mid-development showing as the field has seen.

Retatrutide remains investigational and is not approved by the FDA or any regulatory authority. This page summarizes published clinical-trial and conference data for educational purposes; it is not medical advice.